跳至主要内容
临床试验/ISRCTN87042793
ISRCTN87042793已完成未知

Evaluation of the impact of fermented milk containing Lactobacillus casei strain Shirota (LcS) on stool consistency in healthy subjects producing hard stools

Yakult Honsha (Japan)0 个研究点目标入组 120 人开始时间: 2021年6月24日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
120

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

性别
All

入选标准

  • 1. Informed consent obtained before any study-related activities
  • 2. Healthy female or male aged 18–65 years (inclusive)
  • 3. Produces hard stools (BS1 and 2 stools) with a frequency of 50% or more during 2 weeks of screening data period (between V1 or Call 1, depending on if a washout period is required, and V2)
  • 4. Produces hard stool with log-transformed TAXT median value of >4.5 (ln g) during 5 days of screening stool collection, this after the 2 weeks data collection determined in inclusion criteria 3
  • 5. Is willing and able to collect every stool at home during 5 consecutive days and this 1 time during the screening period and 2 times during the treatment period, to store the samples in appropriate conditions and to return the samples within the required timeframe
  • 6. Is willing and able to complete an electronic diary on an internet-connected device (smartphone, tablet, laptop,..) during the screening and treatment period in order to collect information about the form of the stools (based on the Bristol Stool Form Scale classification) and bowel habit
  • 7. Prepared not to change the current drinking, eating, smoking and exercising habits during the course of the study
  • 8. Understands the Dutch, French or English language (reading, writing, speaking)

排除标准

  • 1. Language barrier, mental or legal incapacity, unwillingness or inability to understand or not being able to participate in the study
  • 2. Is vegetarian or vegan
  • 3. Is treated (i.e., currently treated, treated within 1 month before screening) by a doctor for her/his constipation
  • 4. Has any history of gastrointestinal surgery except for appendectomy
  • 5. Has any history of chronic/severe gastrointestinal disorders
  • 6. Females of child-bearing potential who are pregnant, breastfeeding or intend to become pregnant or are not using adequate contraceptive methods (e.g., oral contraceptive, intrauterine device, abstinence)
  • 7. Is unable to refrain from or anticipates the use of antibiotics and/or laxatives
  • 8. Has any history of drug and/or alcohol abuse
  • 9. Has milk allergies
  • 10. Is intolerant to lactose
  • 11. Any clinically significant disease which in the Investigator’s opinion could interfere with the safety of study participants or with the results of the study
  • 12. Use of disallowed concomitant medications and concomitant products (see section 13) within 2 weeks before the start of screening data collection. If the subject takes any of these medications or products, a washout period of 2 weeks is needed (Optional call 1)
  • 13. Cancer (past or present, except basal cell skin cancer or squamous cell skin cancer), which in the Investigator’s opinion could interfere with the results of the study
  • 14. Previous participation in this study. Participation is defined as screened. Re-screening is therefore not allowed
  • 15. Participation in another interventional clinical study or receipt of any investigational product within 1 month before Visit 1

研究者

发起方
Yakult Honsha (Japan)

相似试验